Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Salicylic acid, Mucopolysaccharide polysulfate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Please read the back of this leaflet.
MOVELAT_REL_0,2_2G_CRE_TR_GB_PIL_9354139_2309 148×420.indd 1
93541392309 GB
06.10.23 12:47
5. HOW TO STORE MOVELAT RELIEF CREAM Keep this medicine out of the sight and reach of children. Do not use Movelat Relief Cream after the expiry date which is stated on the tube and carton after EXP. The expiry date refers to the last day of that month. Store below 25°C. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. CONTENTS OF THE PACK AND OTHER INFORMATION What Movelat Relief Cream contains The active substances are:
Marketing Authorisation Holder: Thornton & Ross Ltd. Linthwaite, Huddersfield, HD7 5QH, UK. Manufacturers: Mobilat Produktions GmbH Luitpoldstrasse 1, 85276 Pfaffenhofen, Germany. This leaflet was last revised in September 2023.
MOVELAT_REL_0,2_2G_CRE_TR_GB_PIL_9354139_2309 148×420.indd 2
93541392309 GB
06.10.23 12:47
Movelat Relief Cream comes as cream. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Movelat Relief Cream is salicylic acid, mucopolysaccharide polysulfate.
Medicines with the same active substance, strength and form include: Movelat Cream. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Movelat Relief Cream, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Movelat/Movelat Relief is a mild to moderate anti-inflammatory and analgesic topical preparation for the symptomatic relief of muscular pain and stiffness, sprains and strains and pain due to rheumatic and non-serious arthritic conditions.
Adults, the elderly and children over 12 years of age:
Two to six inches (5 -15 cm) to be massaged to the affected area up to four times a day.
Children:
The use of Movelat/Movelat Relief is contra-indicated in children under 12 years of age.
Keep away from the eyes. Not to be used on large areas of skin, broken or sensitive skin, infected skin, eczema or on mucous membranes.
Not to be used on children under 12 years of age.
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Hypersensitivity to aspirin or other non-steroidal anti-inflammatory drugs (including when taken by mouth) especially where associated with a history of asthma.
Not to be used on the breast area during lactation (see section 4.6).
For external use only. The stated dose should not be exceeded. If the condition persists or worsens, consult a doctor or pharmacist. Although systemic absorption of topical salicylate is much less than for oral dosage forms, the side effects of salicylates are theoretically possible.
Consult a doctor or pharmacist before use if pregnant, breast-feeding, asthmatic have pre-existing renal damage or on any prescribed medicines.
Some people may experience discomfort, particularly those with sensitive skin or if used in hot weather or after a bath. Wash hands immediately after use.
Discontinue use if excessive irritation or other unwanted effects occur.
Do not smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.
Ingredients with specified warnings
This medicine contains cetostearyl alcohol and lanolin which may cause local skin reactions (e.g. contact dermatitis).
Although no adequately controlled interaction studies have been undertaken, it is possible that excessive use of topical salicylates may increase the effect of coumarin anticoagulants. It is therefore advisable that caution be exercised with patients who are taking coumarin anticoagulants.
Salicylic acid may increase skin permeability for other topically applied medications (see section 5.1).
As with most medicines, patients must seek the doctor's or pharmacist's advice before using if they are pregnant or breast feeding.
Pregnancy
Do not use during the first trimester or during late pregnancy.
Breastfeeding
Not to be used on the breast area during lactation.
In this section, frequencies of undesirable effects are defined as follows: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Skin and subcutaneous tissue disorders
Uncommon: Local skin reactions/irritations (e.g. redness, burning sensation or rashes).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store
Overdose associated with localised/topical application is unlikely.
Following accidental ingestion of Movelat/Movelat Relief, individuals may present with the symptoms of salicylate poisoning (hyperventilation, tinnitus, deafness, vasodilation, sweating). The stomach should be emptied and plasma salicylate, plasma pH and electrolytes should be monitored. Forced alkaline diuresis may be required if the plasma salicylate levels are in excess of 500 mg/litre (3.6 mmol/litre) in adults or 300 mg/litre (2.2 mmol/litre) in children.
Ask anything about Movelat Relief Cream. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.